Atossa Genetics Inc. is a healthcare company focused on the development and marketing of cellular and molecular diagnostic risk assessment products for breast cancer. The Company's diagnostic tests consist of medical devices which can collect fluid samples from the breast milk ducts. It is also conducting research on the treatment of pre-cancerous cells by using its FDA-cleared microcatheters to deliver, directly into the milk ducts, anti-cancer drugs that can be used to treat the pre-cancerous lesions. Atossa Genetics Inc. is headquartered in Seattle, WA....
+See MoreSharpe-Lintner-Black CAPM alpha (Premium Members Only) Fama-French (1993) 3-factor alpha (Premium Members Only) Fama-French-Carhart 4-factor alpha (Premium Members Only) Fama-French (2015) 5-factor alpha (Premium Members Only) Fama-French-Carhart 6-factor alpha (Premium Members Only) Dynamic conditional 6-factor alpha (Premium Members Only) Last update: Saturday 7 March 2026
2023-01-09 10:31:00 Monday ET

Response to USPTO fintech patent protection As of early-January 2023, the U.S. Patent and Trademark Office (USPTO) has approved our U.S. utility patent
2017-03-15 08:46:00 Wednesday ET

The heuristic rule of *accumulative advantage* suggests that a small fraction of the population enjoys a large proportion of both capital and wealth creatio
2021-05-20 10:30:00 Thursday ET

Artificial intelligence, 5G, and virtual reality can help transform global trade, finance, and technology. Core trade technological advances and disruptive
2023-02-28 10:27:00 Tuesday ET

Basic income reforms can contribute to better health care, public infrastructure, education, technology, and residential protection. Philippe Van Parijs
2018-05-17 07:41:00 Thursday ET

Has America become a democratic free land of crumbling infrastructure, galloping income inequality, bitter political polarization, and dysfunctional governa
2025-05-29 08:25:28 Thursday ET

Serial venture capitalist Ben Horowitz describes many hard truths, lessons, and insights from his entrepreneurial journey of running LoudCloud from a Silico